| Trial ID: | L0050 |
| Source ID: | NCT03646292
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NAFLD - Nonalcoholic Fatty Liver Disease|Type2 Diabetes
|
| Interventions: |
Drug: Pioglitazone|Drug: Empagliflozin|Drug: Combination of pioglitazone and empagliflozin
|
| Outcome Measures: |
liver fat change measured by MRI-PDFF in co-localized regions of interest within each of nine liver segments|Liver fibrosis measured by magnetic resonance elastography|The changes in lipid profile|The changes in liver enzyme|The changes in glucose metabolism|The changes in inflammation status
|
| Sponsor/Collaborators: |
Yonsei University
|
| Gender: |
All
|
| Age: |
19 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 4
|
| Enrollment: |
60
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
December 19, 2018
|
| Completion Date: |
February 2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
October 19, 2020
|
| Locations: |
Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, Korea, Republic of
|
| URL: |
https://ClinicalTrials.gov/show/NCT03646292
|
